VistaGen Therapeutics, Inc. (VTGN) Earnings History
Net Loss18 years of earnings data (2009–2026) · Currently unprofitable on a TTM basis
Loading earnings history...
VistaGen Therapeutics, Inc. (VTGN) Earnings Overview
As of June 28, 2026, VistaGen Therapeutics, Inc. (VTGN) reported trailing twelve-month net income of -$70M, reflecting -9.6% year-over-year growth. The company earned $-1.83 per diluted share over the past four quarters, with a net profit margin of -5491.3%.
Looking at the long-term picture, VTGN's historical earnings data spans multiple years. The company achieved its highest annual net income of -$8,976 in fiscal 2011.
VistaGen Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PRAX (-$327M net income), ALTO ($29M net income, 1.5% margin), AXSM (-$188M net income, -28.7% margin), VTGN has comparable earnings metrics. Compare VTGN vs PRAX →
VTGN Earnings vs Peers
Earnings metrics vs comparable public companies
VTGN Historical Earnings Data (2009–2026)
18 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2026 | -$70M | -35.5% | -$72M | $-1.83 | -5491.3% | -5683.7% |
| 2025 | -$51M | -75.1% | -$56M | $-1.67 | -10579.8% | -11517.1% |
| 2024 | -$29M | +50.4% | -$33M | $-1.52 | -2759.6% | -3103.5% |
| 2023 | -$59M | -24.0% | -$59M | $-8.51 | - | - |
| 2022 | -$48M | -166.3% | -$48M | $-7.38 | -4307.2% | -4308.7% |
| 2021 | -$18M | +13.7% | -$18M | $-14.74 | -1646.1% | -1646.1% |
| 2020 | -$21M | +15.5% | -$20M | $-14.21 | - | - |
| 2019 | -$25M | -71.4% | -$25M | $-25.83 | - | - |
| 2018 | -$14M | -39.9% | -$14M | $-30.98 | - | - |
| 2017 | -$10M | +78.3% | -$10M | $-40.85 | -820.4% | -819.9% |
| 2016 | -$47M | -240.1% | -$18M | $-801.27 | - | - |
| 2015 | -$14M | -367.9% | -$7M | $-315.87 | - | - |
| 2014 | -$3M | +77.0% | -$5M | $-81.00 | - | - |
| 2013 | -$13M | -5.5% | -$7M | $-426.98 | -6430.5% | -3389.8% |
| 2012 | -$12M | -135923.8% | -$9M | $-497.11 | -909.7% | -673.8% |
| 2011 | $-8,976 | +59.2% | $-8,946 | $-0.46 | - | - |
| 2010 | $-21,998 | -34.0% | $-21,968 | $-1.13 | - | - |
| 2009 | $-16,416 | - | $-16,386 | $-0.95 | - | - |
Download Data
Export VTGN earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
17+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
VTGN — Frequently Asked Questions
Quick answers to the most common questions about buying VTGN stock.
What is VTGN earnings per share (EPS)?
VTGN trailing twelve-month (TTM) diluted EPS is $-1.83, reflecting -9.6% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2009 to 2026 is available in the table on this page.
What is VistaGen Therapeutics, Inc.'s net income?
VistaGen Therapeutics, Inc. (VTGN) trailing twelve-month net income is $-70M as of 2026. Earnings declined -9.6% year-over-year.
Is VTGN profitable?
VTGN is not currently profitable on a TTM basis, reporting a net loss of $-70M. Net margin is -5491.3%. Investors should monitor for a return to profitability.
What is VTGN's earnings growth rate?
VTGN compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2009 to 2026.
What are VTGN's profit margins?
VistaGen Therapeutics, Inc. net profit margin is -5491.3%, operating margin is -5683.7%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -131.6%.
Is VTGN growing earnings?
VTGN earnings are declining — EPS fell -9.6% year-over-year. TTM net income dropped to $-70M. This contrasts with the 5-year CAGR of N/A.
What was VTGN's best earnings year?
VistaGen Therapeutics, Inc.'s highest annual net income on record is $-8976.00, achieved in fiscal year 2011. Earnings history on this page spans 2009 to 2026 and includes all annual and quarterly figures.
What were VTGN's earnings last quarter?
VTGN's most recent reported quarter was Q4 2026. Net income was $-16M with diluted EPS of $-0.41. For a full breakdown of all quarters, see the quarterly earnings table on this page.